Colorectal Cancer - Drug Pipeline Analysis and Market Forecasts to 2016

London, United Kingdom (PressExposure) January 06, 2010 -- GlobalData estimated the colorectal cancer (CRC) market to be worth $6 billion in 2009 with a projected Compound Annual Growth Rate (CAGR) of 9.8% and projected market value to exceed $11.6 billion in 2016. Replacement of chemotherapies by target therapies in adjuvant treatments and neo adjuvant therapies has boosted the sales of CRC therapeutics market. Further, approval of costly target therapies such as Avastin and Erbitux for first-line metastatic colorectal cancer have driven the sales of the CRC therapeutics market.

For further details, please click or add the below link to your browser: http://www.global-market-research-data.com/Report.aspx?ID=Colorectal-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

GlobalData analyzed that AstraZeneca has one of the most promising drugs (Recentin) in Phase III clinical development which is expected to hit the market by the second half of 2010. Roche/Genentech's Avastin has generated $4.8 billion with 28.5% share in total Roche’s oncology market for the year 2008 and is expected to increase to $9.6 billion by 2016. Companies such as Sanofi-aventis, Bristol-Myers Squibb, Novartis AG, GlaxoSmithKline, Amgen, Biogen Idec, Pfizer, Merck & Co, and Eli Lilly have some of the most technologically advanced products in their pipeline portfolio, and are therefore expected to attract investors’ attention.

For further details, please click or add the below link to your browser: http://www.global-market-research-data.com/Report.aspx?ID=Colorectal-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

GlobalData has found that products for colorectal cancer in developmental pipeline are strong with over 158 molecules in various phases of clinical development. There are more than 77 first-in-class molecules in different stages of clinical development. These molecules have a distinct advantage over the current market players and display robustness in the CRC pipeline. Chemotherapy with or without combinational targeted therapies may improve the symptoms and prolong the life of the cancer patients. Huge research activities in combinational targeted therapies are ongoing in the R&D sectors.

Aflibercept, Recentin, OncoVax, TroVax and Brivanib are the most promising molecules currently in the pipeline. These targeted drugs from a new class of therapies hold a promise to add value to CRC market in the near future and may strongly compete with current market players on the basis of better efficacy and safety profile leading to overall patient and physician satisfaction.

GlobalData, the industry analysis specialist, has released its latest research, “Colorectal Cancer (CRC) – Drug Pipeline Analysis and Market Forecasts to 2016” which provides key data, information and analysis on the CRC market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecasts forward seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with CRC, competitive assessment, product profiles of major marketed products and promising drugs in the pipeline, an overview on discontinued projects, implications for future market competition, and the key players of the CRC market.

For further details, please click or add the below link to your browser: http://www.global-market-research-data.com/Report.aspx?ID=Colorectal-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

Or visit our report store: http://www.globaldata.com/reportstore

About GlobalData

GlobalData is a global market intelligence services company providing information research and analysis products and services.

Press Release Source: http://PressExposure.com/PR/GlobalData.html

Press Release Submitted On: January 06, 2010 at 4:04 am
This article has been viewed 14811 time(s).